XLO

Xilio Therapeutics, Inc. (XLO) | Rumor.io

Xilio Therapeutics

XLO

Attention (50-day avg)0%

Attention rank (50-day avg)#3,912

Bullish sentiment (50-day avg)100%

Price to earnings ratio-2.16

Market capitalization59.6M

Earnings per share-0.32

Dividend yield (TTM)—

Revenue (annual)43.8M

Net income (annual)-35M

Social

What share of all stock conversation is about XLO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% 0	0% 0

Mar 24

Xilio Therapeutics, Inc. (XLO) has a cash position of approximately $200 million, with a market cap of $40 million.
The company has a significant cash buffer, with a pro forma cash position of $179.8 million, representing 73% of its fully diluted market cap.
XLO is eligible for up to $2.1 billion in contingent payments from its collaboration with Abbvie, including potential milestone payments for the remainder of 2026.

Generated by AI

Sentiment

Of the messages about XLO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	100% 0	82.81% -3.55
Bearish	—	0%	0% 0	17.19% +3.55

Bullish· Sep 9

Xilio Therapeutics' ($XLO) Phase 2 trial for its cancer drug XTX301, in partnership with Gilead Sciences, is a significant milestone that could drive the stock price up.
The company's $140 million cash reserve and $38 million market cap make it an attractive investment opportunity, with the potential for the stock to climb quickly.
A successful Phase 2 trial and potential collaboration with Gilead could inject capital, driving the stock price above analysts' target of $3.00.

Bearish· Jun 2

The company's announcement of warrants ahead of finalization may be a scare tactic to push out bad traders and create a buying opportunity.
The surprise public offering may be a dilution play to push the share price down and allow the company to raise more capital.
The company's timing of the offering, immediately after presenting positive data, may be a bad move that has already led to a significant drop in the stock price.

Generated by AI

Topics

Of the messages about XLO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	79.14%
Technical Analysis	—	—	—	18.72%
Analysts	—	—	—	0.53%
Controversies	—	—	—	0%
Earnings	—	—	—	1.6%
Macro	—	—	—	0%

Announcements· Sep 9

Xilio Therapeutics has initiated Phase 2 trials for its tumor-activated IL-12 therapy, efarindodekin alfa, under an exclusive license agreement with Gilead.
The company has achieved a $17.5 million development milestone under the agreement, which extends its cash runway into Q1 2027 and builds momentum in immuno-oncology.
Xilio Therapeutics has started patient dosing in Phase 2 of its clinical trial for efarindodekin alfa, targeting advanced solid tumors, with Gilead paying a $17.5 million milestone under their deal.

Technical Analysis· May 14

The stock is forming a falling wedge with a flattening slope, and a strong support level at $0.95.
The stock is in a cup and handle formation, and a break above $1.04 could provide momentum.
The stock is oversold on the RSI 5m, with 50k shorts coming into the market, but it could retrace up longer term if it reaches a certain volume.

Generated by AI

Community

Of the messages about XLO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	100%	39.55%
Newcomers	—	0%	0%	60.45%

Sep 9

Xilio Therapeutics has initiated a Phase 2 trial for its cancer therapy efarindodekin alfa (XTX301), a tumor-activated IL-12, and achieved a $17.5 million development milestone under an exclusive license agreement with Gilead.
The company's cash runway has been extended into Q1 2027, with a current cash position of $121.6 million.
A successful Phase 2 trial and potential collaboration with Gilead could drive the stock price above analysts' target of $3.00, with some analysts predicting a price target of $1.2.

Generated by AI

Dr. Houvras brings over two decades of executive leadership across premier industry and academic research institutions in clinical development, translational medicine and immuno-oncologyWALTHAM, Mass., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced the appointment of Dr. Yariv Houvras as chief medical officer. “We are thrill

2d agoYahoo! Finance Canada

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that, effective September 1, 2026, the company granted non-qualified stock options to purchase 19,865 shares of its common stock to two new employees under Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan. The stock options have an exercise price of $8.88

27d agoYahoo Finance

Xilio Therapeutics earnings beat by $0.25, revenue topped estimates

1mo agoInvesting.com

Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates

Received FDA clearance of IND application for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2 Advancing IND-enabling studies for potential first-in-class multi-specific, masked T cell engager programs targeting CLDN18.2 and PSMA+STEAP1; IND applications anticipated in the second half of 2027 Cash runway into the first quarter of 2028 expected to support key milestones across pipeline of next generation multi-specific I-O therapies WALTHAM, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) --

1mo agoYahoo Finance UK

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that, effective July 1, 2026, the company granted non-qualified stock options to purchase 107,060 shares of its common stock to three new employees under Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan. The stock options have an exercise price of $9.22 pe

2mo agofinance.yahoo.com

Also Discussed

Investors talking about XLO also mention

#	Name	Attention
1	CytomX Therapeutics, Inc.CTMX	0%0
2	NewGenIvf Group Limited Class A Ordinary SharesNIVF	0%0
3	PMV Pharmaceuticals, Inc.PMVP	0%0
4	FBS Global LimitedFBGL	0%0
5	Lyell Immunopharma, Inc.LYEL	0.01%new
6	ABP - Abpro Corporation	——
7	KRON - Kronos Bio, Inc.	——
8	Bit Origin Ltd. Class A Ordinary SharesBTOG	0%0
9	Atif Holdings Ltd.ZBAI	0%0
10	AGM Group Holdings IncAGMH	0%0

Xilio Therapeutics, Inc.

Healthcare
Biotechnology

Xilio Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing tumor-activated immuno-oncology therapies designed to enhance anti-cancer immune responses. The company's pipeline includes vilastobart, a tumor-activated, Fc-enhanced anti-CTLA-4 antibody being evaluated in combination with atezolizumab for advanced solid tumors and microsatellite stable metastatic colorectal cancer, and efarindodekin alfa, a tumor-activated IL-12 molecule in clinical trials for advanced solid tumors. Xilio is also advancing XTX501, a bispecific PD-1/masked IL-2 molecule, and multiple masked T cell engager programs targeting tumor-associated antigens including PSMA, CLDN18.2, and STEAP1. The company's masked immunotherapy platform aims to selectively activate immune responses within the tumor microenvironment while minimizing systemic side effects. Xilio maintains strategic collaborations with major pharmaceutical partners, including an agreement with AbbVie to develop novel tumor-activated antibody-based immunotherapies, and generates collaboration revenue to extend its development runway.

Website

Location

828 Winter Street

Waltham, MA, 02451

United States

Social

What share of all stock conversation is about XLO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% 0	0% 0

Mar 24

Xilio Therapeutics, Inc. (XLO) has a cash position of approximately $200 million, with a market cap of $40 million.
The company has a significant cash buffer, with a pro forma cash position of $179.8 million, representing 73% of its fully diluted market cap.
XLO is eligible for up to $2.1 billion in contingent payments from its collaboration with Abbvie, including potential milestone payments for the remainder of 2026.

Generated by AI

Sentiment

Of the messages about XLO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	100% 0	82.81% -3.55
Bearish	—	0%	0% 0	17.19% +3.55

Bullish· Sep 9

Xilio Therapeutics' ($XLO) Phase 2 trial for its cancer drug XTX301, in partnership with Gilead Sciences, is a significant milestone that could drive the stock price up.
The company's $140 million cash reserve and $38 million market cap make it an attractive investment opportunity, with the potential for the stock to climb quickly.
A successful Phase 2 trial and potential collaboration with Gilead could inject capital, driving the stock price above analysts' target of $3.00.

Bearish· Jun 2

The company's announcement of warrants ahead of finalization may be a scare tactic to push out bad traders and create a buying opportunity.
The surprise public offering may be a dilution play to push the share price down and allow the company to raise more capital.
The company's timing of the offering, immediately after presenting positive data, may be a bad move that has already led to a significant drop in the stock price.

Generated by AI

Topics

Of the messages about XLO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	79.14%
Technical Analysis	—	—	—	18.72%
Analysts	—	—	—	0.53%
Controversies	—	—	—	0%
Earnings	—	—	—	1.6%
Macro	—	—	—	0%

Announcements· Sep 9

Xilio Therapeutics has initiated Phase 2 trials for its tumor-activated IL-12 therapy, efarindodekin alfa, under an exclusive license agreement with Gilead.
The company has achieved a $17.5 million development milestone under the agreement, which extends its cash runway into Q1 2027 and builds momentum in immuno-oncology.
Xilio Therapeutics has started patient dosing in Phase 2 of its clinical trial for efarindodekin alfa, targeting advanced solid tumors, with Gilead paying a $17.5 million milestone under their deal.

Technical Analysis· May 14

The stock is forming a falling wedge with a flattening slope, and a strong support level at $0.95.
The stock is in a cup and handle formation, and a break above $1.04 could provide momentum.
The stock is oversold on the RSI 5m, with 50k shorts coming into the market, but it could retrace up longer term if it reaches a certain volume.

Generated by AI

Community

Of the messages about XLO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	100%	39.55%
Newcomers	—	0%	0%	60.45%

Sep 9

Xilio Therapeutics has initiated a Phase 2 trial for its cancer therapy efarindodekin alfa (XTX301), a tumor-activated IL-12, and achieved a $17.5 million development milestone under an exclusive license agreement with Gilead.
The company's cash runway has been extended into Q1 2027, with a current cash position of $121.6 million.
A successful Phase 2 trial and potential collaboration with Gilead could drive the stock price above analysts' target of $3.00, with some analysts predicting a price target of $1.2.

Generated by AI

Xilio Therapeutics

Social

Mar 24

Sentiment

Bullish· Sep 9

Bearish· Jun 2

Topics

Announcements· Sep 9

Technical Analysis· May 14

Community

Sep 9

News

Xilio Therapeutics appoints Yariv Houvras as chief medical officer

Xilio Therapeutics Appoints Yariv J. Houvras, M.D., Ph.D. as Chief Medical Officer

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Xilio Therapeutics earnings beat by $0.25, revenue topped estimates

Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Also Discussed

Xilio Therapeutics, Inc.

Company Information

Location

News

Xilio Therapeutics appoints Yariv Houvras as chief medical officer

Xilio Therapeutics Appoints Yariv J. Houvras, M.D., Ph.D. as Chief Medical Officer

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Xilio Therapeutics earnings beat by $0.25, revenue topped estimates

Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Also Discussed

Social

Mar 24

Sentiment

Bullish· Sep 9

Bearish· Jun 2

Topics

Announcements· Sep 9

Technical Analysis· May 14

Community

Sep 9